American Association for Cancer Research

Continuing Medical Education (CME)


The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.


AACR has designated this live activity for a maximum of 20.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above. 


Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by December 13, 2013. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via e-mail after the completion of the activity.


Cancer is the leading cause of death by a disease in U.S. children under 15 years old. Approximately 11,630 new cases of childhood cancer are expected to be diagnosed in 2013 and 1,310 children are expected to die. The majority of cancer therapies available are generally developed for adults and their efficacy in treating childhood cancers is unknown. From 1948 to 2003, regulators approved 120 new cancer therapies. However, only 15 contained information about pediatric use. Thus there is an urgent need to develop therapeutic approaches specific to the treatment of childhood cancers and educate physicians and investigators on the newest approaches available based on recent research.

Pediatric cancers differ significantly from adult cancers. For example, childhood cancers are found in different areas of the body than adult cancers. Leukemias and brain and other central nervous system tumors comprise the major types of childhood cancers and account for more than half of new cases. Survival rates for childhood cancers vary depending on the type of cancer and other factors. Additionally, most childhood cancers cannot be prevented, and the precise cause of most childhood cancers is unknown. Unlike adult cancers, childhood cancers are not strongly linked to environmental or lifestyle risk factors but can depend on genetic factors. Thus, the ability to translate recent advances in genomics and epigenomics into clinical practice and apply them to generate effective treatments is key to combatting childhood cancers. Additionally, immune therapy approaches and therapies targeting biologic drivers are important. The central role of translational research and clinical trials is highlighted by the fact that declines in the mortality rate from a number of childhood cancers can be attributed to improved treatments and a high proportion of participation in clinical trials. This conference will bring together top basic, translational, and clinical researchers in the field to discuss recent findings in genomics/epigenomics, developmental biology, immune therapies, and cellular mechanisms and how these translate into new therapeutic approaches for childhood brain tumors, leukemias, neuroblastomas, and sarcomas. The conference will also address the opportunities and challenges in pediatric oncology translational science and clinical trials.

To combat pediatric cancers, there is a need to educate physicians on the role of the various factors involved in the development of childhood cancers and how basic research findings can be translated effectively to the clinic to develop new therapeutic approaches. This conference will bring together a wide range of physicians, scientists, health professionals, and health care leaders to discuss the latest findings in their fields, to foster collaborative interdisciplinary interactions and partnerships, and to stimulate the development of new research and clinical practices.

After participating in this CME activity, physicians should be able to:

  1. Articulate how to apply genomics and epigenomics data to identify diagnostic biomarkers, drivers, and therapeutic targets for pediatric cancers;
  2. Compare various targeted therapeutic approaches to childhood neuroblastoma, leukemias, brain tumors, and sarcomas;
  3. Explain the cellular mechanisms, biologic drivers, and genetic factors that underlie pediatric malignancies;
  4. Identify immune-based therapies for childhood cancer;
  5. Assess the impact of new genomic data on clinical practice, particularly how to leverage the vast amount of data generated from diverse sources to develop evidenced-based protocols to drive clinical decisions in the treatment of pediatric cancer.


It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.


This activity is supported by grants that will be disclosed at the activity. 


Please contact the Office of CME at (215) 440-9300 or